FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC

doi:10.4329/wjr.v6.i7.392

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 7

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5356)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

424

WORD

285

HTML

2791

Tables (1-4)

198

Sum=3698

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

847

Download

811

Sum=1658

Jul 28, 2014 (publication date) through Apr 28, 2024

Times Cited of This Article

Times Cited (33)

Journal Information of This Article

Publication Name

World Journal of Radiology

ISSN

1949-8470

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Radiol. Jul 28, 2014; 6(7): 392-398
Published online Jul 28, 2014. doi: 10.4329/wjr.v6.i7.392

FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC

Matthijs H van Gool, Tjeerd S Aukema, Koen J Hartemink, Renato A Valdés Olmos, Harm van Tinteren, Houke M Klomp

Matthijs H van Gool, Koen J Hartemink, Houke M Klomp, Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands

Tjeerd S Aukema, Renato A Valdés Olmos, Department of Nuclear Medicine, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands

Harm van Tinteren, Department of Biometrics, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands

Author contributions: All authors contributed equally on this manuscript in accordance with the standard proposed by the International Committee of Medical Journal Editors.

Correspondence to: Houke M Klomp, MD, PhD, Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. h.klomp@nki.nl

Telephone: +31-20-5122554 Fax: +31-20-5129111

Received: January 23, 2014
Revised: April 28, 2014
Accepted: May 16, 2014
Published online: July 28, 2014

Core Tip

Core tip: Our report shows that response monitoring using [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) acquired together with low dose computed tomography has potential in targeted treatment for non-small cell lung cancer and can be performed as early as 1-2 wk after initiation of treatment. Patients with substantial decrease of metabolic activity during epidermal growth factor receptor-tyrosine kinase inhibitors treatment will probably benefit from continued treatment. Refining FDG-PET response criteria may help the clinician to decide on continuation or discontinuation of targeted treatment.